NewAmsterdam Pharma (NAMS) Depreciation & Amortization (CF) (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Depreciation & Amortization (CF) of $62000.0 for Q1 2026, up 19.23% on a YoY basis from $52000.0 in Q1 2025, and up 5.08% sequentially from $59000.0 in Q4 2025.
NewAmsterdam Pharma (NAMS) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $62000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 19.23% year-over-year to $62000.0; the trailing twelve-month figure through Mar 2026 stood at $230000.0 (up 53.33% YoY), and the FY2025 full-year result was $220000.0, up 94.69% from the prior year.
- Depreciation & Amortization (CF) advanced to $62000.0 in Q1 2026, from $59000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $64000.0 in Q3 2025 to a low of $9000.0 in Q1 2023.
- A 4-year average of $35916.7 and a median of $36500.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) jumped 292.31% in 2024 and climbed 15.69% in 2025, its largest moves.
- Tracing NAMS's Depreciation & Amortization (CF) over 4 years: stood at $13000.0 in 2023, then jumped by 292.31% to $51000.0 in 2024, then rose by 15.69% to $59000.0 in 2025, then increased by 5.08% to $62000.0 in 2026.
- Business Quant data shows NAMS's Depreciation & Amortization (CF) at $62000.0 in Q1 2026, $59000.0 in Q4 2025, and $64000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | 62,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,000.00 |
| Mar 31, 2026 | 62,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Mar 31, 2025 | 52,000.00 |
| Mar 31, 2025 | 52,000.00 |
| Dec 31, 2024 | 51,000.00 |
| Dec 31, 2024 | 51,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Dec 31, 2023 | 13,000.00 |